Company Overview and News

 
Here's Why I'm Buying Whirlpool

2018-01-24 seekingalpha
At 2.5%, the dividend yield is quite reasonable and well above the 5 year average of 2.0%.
Upvote Downvote

 
Global Trade Boom Steams Into 2018 as Trump Threatens Barriers - Bloomberg

2017-11-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Tech share plunge drags Asian stocks lower

2017-11-30 thehindubusinessline
Asian shares fell on Thursday, weighed down by a plunge in high-flying technology shares, a move that some see as a healthy correction after a strong rally but others believe may herald the peak of a “super cycle” that has been boosting the sector.
Upvote Downvote

 
Asian stocks fall as tech bellwethers hit by fear boom has peaked

2017-11-30 in.reuters
TOKYO (Reuters) - Asian shares fell on Thursday, weighed down by a plunge in high-flying technology shares, a move that some see as a healthy correction after a strong rally but others believe may herald the peak of a “super cycle” that has been boosting the sector.
Upvote Downvote

 
Asian stocks fall as tech bellwethers hit by fear boom has peaked

2017-11-30 channelnewsasia
Asian shares fell on Thursday, weighed down by a plunge in high-flying technology shares, a move that some see as a healthy correction after a strong rally but others believe may herald the peak of a "super cycle" that has been boosting the sector.
Upvote Downvote

 
Tech share plunge drags Asian stocks lower

2017-11-30 moneycontrol
Asian shares fell on Thursday, weighed down by a plunge in high-flying technology shares, a move that some see as a healthy correction after a strong rally but others believe may herald the peak of a "super cycle" that has been boosting the sector.
Upvote Downvote

 
Apple paid $100 million-plus for kiwi tech company PowerbyProxi

2017-11-30 nzherald.co.nz
Apple Inc was granted Overseas Investment Office approval to buy PowerbyProxi last month for a consideration exceeding $100 million.
Upvote Downvote

 
Listen Up, Retailers: Don't Ignore Voice Shopping - Bloomberg Gadfly

2017-11-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Wall Street tech share plunge drags Asian stocks lower

2017-11-30 themalaymailonline
People walk past an electronic stock quotation board outside a brokerage in Tokyo September 22, 2017. — Reuters picTOKYO, Nov 30 — Asian shares fell yesterday, weighed down by a plunge in high-flying technology shares, a move that some see as a healthy correction after a strong rally but others believe may herald the peak of a “super cycle” that has been boosting the sector.
Upvote Downvote

 
Tech share plunge drags Asian stocks lower - Channel NewsAsia

2017-11-30 channelnewsasia
Asian shares fell on Thursday, weighed down by a plunge in high-flying technology shares, a move that some see as a healthy correction after a strong rally but others believe may herald the peak of a "super cycle" that has been boosting the sector.
Upvote Downvote

 
Tech share plunge drags Asian stocks lower

2017-11-30 thestar.com.my
MSCI's broadest index of Asia-Pacific shares outside Japan dropped 0.5 percent, with technology bellwether Samsung Electronics falling 2.9 percent to two-month lows. Japan's Nikkei dipped 0.3 percent, led by falls in Sony, Murata manufacturing and other technology shares. Asia tech shares came under pressure after U.S. hi-tech giants plummeted.
Upvote Downvote

 
Tech share plunge drags Asian stocks lower

2017-11-30 in.reuters
TOKYO (Reuters) - Asian shares fell on Thursday, weighed down by a plunge in high-flying technology shares, a move that some see as a healthy correction after a strong rally but others believe may herald the peak of a “super cycle” that has been boosting the sector.
Upvote Downvote

 
Tech share plunge drags Asian stocks lower

2017-11-30 reuters
TOKYO (Reuters) - Asian shares fell on Thursday, weighed down by a plunge in high-flying technology shares, a move that some see as a healthy correction after a strong rally but others believe may herald the peak of a “super cycle” that has been boosting the sector.
Upvote Downvote

 
Popular tech stocks like Nvidia, Facebook are getting smoked

2017-11-29 cnbc
So-called FANG stocks are all dropping with Facebook down 3.8 percent, Amazon off by 2.6 percent, Netflix falling 5 percent and Google parent Alphabet lower by 2.5 percent.
Upvote Downvote

1
Electric Vehicle Market Powered Up To Accelerate

2017-11-29 seekingalpha
As the pace of improvement in fuel economy required by governments around the world have been picking up since 2015, China's new energy car mandatory production system and the US Zero Emission Vehicle (ZEV) program are practically forcing automakers to boost the sales of electric vehicles such as battery electric vehicles (BEVS) and plug-in electric vehicles (PHEVs). European automakers, which were not as enthusiastic about EVs as others, have also joined the movement toward the electrification of powertrains since the 'Dieselgate' scandal.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 796050201